Profile
Settings
Refer your friends
Sign out
Why in the News?
Union Minister of Science and Technology announced the scientific completion of Cervavac, India’s first indigenously developed vaccine for cervical cancer.
Key Points:
About Cevavac:
- Developed by: Serum Institute of India in coordination with the Government of India’s Department of Biotechnology (DBT).
- It received market authorisation approval from the Drug Controller General of India in July 2022.
Cervical Cancer
- Cervical cancer is the most common Human Papillomavirus (HPV)-related disease.
- Human papillomavirus (HPV) is the most common viral infection of the reproductive tract.
- It is the fourth most common cancer among women globally, according to the WHO.
- It is preventable if detected early and managed effectively.
Screening and vaccination are two powerful tools that are available for preventing cervical cancer.
Prevalence of Cervical cancer in India
- Cervical cancer is the leading cancer among women, with about 132,000 cases annually and 74,000 deaths in India, according to the Indian Council of Medical Research (ICMR).
- India contributes 17 per cent of the world’s population but shares more than a quarter of the global cervical cancer burden.
